Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-08-09
2008-08-12
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S515000, C548S452000
Reexamination Certificate
active
07410993
ABSTRACT:
This invention generally relates to the derivatives of 3,6 disubstituted azabicyclo[3.1.0] hexanes. The compounds of this invention are muscarinic receptor antagonists which are useful, inter-alia, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention, pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
REFERENCES:
patent: 3176019 (1965-03-01), Campbell et al.
patent: 4183857 (1980-01-01), Kollmeyer
patent: 5281601 (1994-01-01), Cross et al.
patent: 5948792 (1999-09-01), Tsuchiya et al.
patent: 6130232 (2000-10-01), Mase et al.
patent: 6174900 (2001-01-01), Okada et al.
patent: 6191165 (2001-02-01), Ognyanov et al.
patent: 0 325 571 (1989-07-01), None
patent: 0 388 054 (1990-09-01), None
patent: 0 801 067 (1997-10-01), None
patent: 940540 (1963-10-01), None
patent: 92921/1994 (1994-04-01), None
patent: 135989/1994 (1995-05-01), None
patent: WO 89/06644 (1989-07-01), None
patent: WO 91/09013 (1991-06-01), None
patent: WO 93/16018 (1993-08-01), None
patent: WO 93/16048 (1993-08-01), None
patent: WO 96/33973 (1996-10-01), None
patent: WO 97/45414 (1997-12-01), None
patent: WO 98/05641 (1998-02-01), None
patent: WO 98/29402 (1998-07-01), None
Morissette et al. Advanced Drug Delivery Reviews 2004, 56, 275-300.
Wess et al. Life Sciences 2003, 72, 2047-2054.
O'Neill, M. Drug Discovery Today Oct. 2005, 10(20), 1338.
Michel et al. Naunyn-Schmiedeberg's Arch Pharmacol 2006, 374, 79-85.
Latifpour et al. The Journal of Pharmacology and Experimental Therapeutics 1989, 249(1), 81-88.
Carrier et al. The Journal of Pharmacology and Experimental Therapeutics 1987, 242(2), 531-535.
Ahren et al. Diabetologia 1996, 39, 383-390.
Abrams et al. British Journal of Pharmacology 2006, 148, 565-578.
Kubo et al., “Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor”,Nature, 323(2):411-416 (1986).
Bonner et al., “Identification of a Family of Muscarinic Acetylcholine Receptor Genes”,Science, 237:527-531 (1987).
Eglen et al., “Muscarinic receptor ligands and their theraputic potential”,Current Opinion in Chemical Biology, 3:426-432 (1999).
Eglen et al., “Theraputic opportunities from muscarinic receptor research”,Trends in Pharmacological Sciences, 22(8):490-414 (2001).
Felder et al., “Theraputic Opportunities for Muscarinic Receptors in the Central Nervous System”,Journal of Medicinal Chemistry, 43(23):4333-4353 (2000).
Broadley and Kelly, “Muscarinic Receptor Agonists and Antagonists”,Molecules, 6:142-193 (2001).
Birdsall et al., “Muscarinic receptors: it's a knockout”,Trends in Pharmacological Sciences, 22(5):215-219 (2001).
de Groat and Yoshimura, “Pharmacology of the Lower Urinary Tract”,Annual Review of Pharmacology and Toxicology, 41:691-721 (2001).
Steers, “The future direction of neuro-urology drug research”,Current Opinion in CPNS Investigational Drugs, 2(3):268-282, 2000.
Chapple, “Muscarinic receptor antagonists in the treatment of overactive bladder”,Urology, 55(Suppl. 5A):33-46 (2000).
Steers, Barrot, Wein, “Voiding dysfunction: diagnosis classification and management”, In:Adult and Pediatric Urology, ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996).
Sagara et al., “Cyclohexylmethylpiperidinyltriphenylpropioamide: A Selective Muscarinic M3Antagonist Discriminating against the Other Receptor Subtypes”,Journal of Medicinal Chemistry, 45:984-987 (2002).
Moriya et al., “Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland”,Life Sciences, 64(25):2351-2358 (1999).
Cheng and Prusoff, “Relationship between the inihibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction”,Biochemical Pharmacology, 22:3099-3108 (1973).
Bruhaspathy Miriyala
Gupta Jang Bahadur
Mehta Anita
Silamkoti Arundutt V.
Anderson Rebecca L
Deshmukh Esq. Jayadeep R.
Heibel Esq. George E.
Nolan Jason M
Ranbaxy Laboratories Limited
LandOfFree
3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 3,6-disubstituted azabicyclo [3.1.0] hexane deriviatives... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4019093